RIO DE JANEIRO – The first-ever BIO Latin America conference opened Wednesday morning, with roughly 450 registered attendees to talk about the biotech sector, with much of the focus on fostering innovation and collaboration. Read More
RIO DE JANEIRO – Brazil's investments in science and technology have increased by more than 550 percent over the last decade, thanks in large part to a series of innovative programs to reward entrepreneurs and leverage the best research. Read More
LONDON – AM Pharma BV has raised €12.2 million (US$15.8 million) to fund a phase II 290-patient study of its human recombinant alkaline phosphatase product Recap, in what it said will be the largest-ever trial in acute kidney injury. Read More
A Mylan Inc. subsidiary will pay up to $300 million to acquire U.S. commercialization, marketing and IP rights for the anticoagulant Arixtra (fondaparinux) and an authorized generic (AG) of the drug from Aspen Global Inc. in a deal it said will be immediately accretive to adjusted earnings. Read More
TAIPEI, Taiwan – Oncology-focused Aslan Pharmaceuticals Pte. Ltd. has started dosing the first patients in a safety study of its lead compound ASLAN001, a small-molecule, oral pan-HER inhibitor for the treatment of solid tumors. Read More
Ahead of Friday's FDA Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) meeting, briefing materials have been posted related to the biologic license application (BLA) for Natpara (rhPTH[1-84]) developed by NPS Pharmaceuticals Inc., of Bedminster, N.J. Read More
Airway Therapeutics LLC, of Cincinnati, said it secured $4.6 million in a series A financing round with Cincytech leading the round and participation from the Cincinnati Children's Hospital Medical Center, Queen City Angels and private investors. Read More
Cempra Inc., of Chapel Hill, N.C., said it received a $10 million milestone payment from Toyama Chemical Co., a subsidiary of Fujifilm Holdings Corp., triggered by the progress of its solithromycin, which obtained regulatory clearance to begin a phase II trial in Japan. Read More
G1 Therapeutics Inc., of Research Triangle Park, N.C., said it initiated a phase I trial of G1T28-1, a CDK4/6 inhibitor with broad potential in multiple oncology indications. Read More
Eli Lilly and Co., of Indianapolis, and Boehringer Ingelheim GmbH, of Ingelheim, Germany, received marketing authorization for insulin glargine to treat diabetes in the EU, making it the first insulin approved through the biosimilar pathway there. Read More
